Status: Recruiting
Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer
This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).
Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Quanda LiuUpdated: Mar 6, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years; [+6]
Patients with other primary malignant tumors; [+6]